Maria Bjerke1, Silke Kern2,1, Kaj Blennow1, Henrik Zetterberg1,3, Margda Waern2, Anne Börjesson-Hanson2, Svante Östling2, Jürgen Kern2, Ingmar Skoog2. 1. Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 2. Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 3. UCL Institute of Neurology, Queen Square, London, UK.
Abstract
BACKGROUND: Increased fatty acid-binding protein 3 (FABP-3) levels have been reported in neurodegenerative diseases, including Alzheimer's disease (AD). Cerebrospinal fluid (CSF) FABP-3 has therefore been proposed as a putative marker for dementia. Population-based studies examining whether CSF FABP-3 predicts later development of dementia are lacking. OBJECTIVE: The aim of this study was to examine CSF levels of FABP-3 in relation to later development of dementia in elderly women and in relation to Aβ42, T-tau, P-tau181, and CSF: serum albumin ratio. METHODS: 86 non-demented women aged 70-84 years who participated in the Prospective Population Study of Women in Gothenburg, Sweden took part in a lumbar puncture in 1992-93. CSF-FABP-3, Aβ42, T-tau, P-tau181, and the CSF: serum albumin ratio were measured at baseline. Participants were examined with a neuropsychiatric exam at baseline and at follow-up in 2000. Dementia was diagnosed in accordance with DSM-III-R criteria. RESULTS: Between 1992 and 2000, 8 women developed dementia (4 AD, 3 vascular dementia, 1 mixed vascular dementia and AD). Higher levels of CSF-FABP-3 at baseline were related to development of dementia (OR 1.36 CI [1.05-1.76] p = 0.022) and the subtype AD (OR 1.38 CI [1.06-1.82), p = 0.019) during follow-up. FABP-3 correlated with CSF T-tau (r = 0.88, p < 0.001), P-tau181 (r = 0.619, p < 0.001), and CSF:serum albumin ratio (r = 0.233, p = 0.031), but not with Aβ42 (r = -0.08, p = 0.444) CONCLUSION: CSF FABP-3 may be an early marker for later development of dementia, probably related to neuronal degeneration, but independent of Aβ metabolism.
BACKGROUND: Increased fatty acid-binding protein 3 (FABP-3) levels have been reported in neurodegenerative diseases, including Alzheimer's disease (AD). Cerebrospinal fluid (CSF) FABP-3 has therefore been proposed as a putative marker for dementia. Population-based studies examining whether CSFFABP-3 predicts later development of dementia are lacking. OBJECTIVE: The aim of this study was to examine CSF levels of FABP-3 in relation to later development of dementia in elderly women and in relation to Aβ42, T-tau, P-tau181, and CSF: serum albumin ratio. METHODS: 86 non-demented women aged 70-84 years who participated in the Prospective Population Study of Women in Gothenburg, Sweden took part in a lumbar puncture in 1992-93. CSF-FABP-3, Aβ42, T-tau, P-tau181, and the CSF: serum albumin ratio were measured at baseline. Participants were examined with a neuropsychiatric exam at baseline and at follow-up in 2000. Dementia was diagnosed in accordance with DSM-III-R criteria. RESULTS: Between 1992 and 2000, 8 women developed dementia (4 AD, 3 vascular dementia, 1 mixed vascular dementia and AD). Higher levels of CSF-FABP-3 at baseline were related to development of dementia (OR 1.36 CI [1.05-1.76] p = 0.022) and the subtype AD (OR 1.38 CI [1.06-1.82), p = 0.019) during follow-up. FABP-3 correlated with CSF T-tau (r = 0.88, p < 0.001), P-tau181 (r = 0.619, p < 0.001), and CSF:serum albumin ratio (r = 0.233, p = 0.031), but not with Aβ42 (r = -0.08, p = 0.444) CONCLUSION:CSFFABP-3 may be an early marker for later development of dementia, probably related to neuronal degeneration, but independent of Aβ metabolism.
Authors: David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: K Höglund; S Kern; A Zettergren; A Börjesson-Hansson; H Zetterberg; I Skoog; K Blennow Journal: Transl Psychiatry Date: 2017-01-10 Impact factor: 6.222
Authors: Silke Kern; Henrik Zetterberg; Jürgen Kern; Anna Zettergren; Margda Waern; Kina Höglund; Ulf Andreasson; Hanna Wetterberg; Anne Börjesson-Hanson; Kaj Blennow; Ingmar Skoog Journal: Neurology Date: 2018-04-13 Impact factor: 9.910
Authors: Suman De; Daniel R Whiten; Francesco S Ruggeri; Craig Hughes; Margarida Rodrigues; Dimitrios I Sideris; Christopher G Taylor; Francesco A Aprile; Serge Muyldermans; Tuomas P J Knowles; Michele Vendruscolo; Clare Bryant; Kaj Blennow; Ingmar Skoog; Silke Kern; Henrik Zetterberg; David Klenerman Journal: Acta Neuropathol Commun Date: 2019-07-26 Impact factor: 7.801
Authors: Miles Berger; Mary Cooter; Alexander S Roesler; Stacey Chung; John Park; Jennifer L Modliszewski; Keith W VanDusen; J Will Thompson; Arthur Moseley; Michael J Devinney; Shayan Smani; Ashley Hall; Victor Cai; Jeffrey N Browndyke; Michael W Lutz; David L Corcoran Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472